Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitch Dowsett

Showing results (51-60 of 359) with videos related to

Pageof 36
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 11, 2014
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitorsPer Eystein Lønning, Benjamin P Haynes, Mitch Dowsett
Breast Cancer Research and Treatment|October 26, 2005
Life following aromatase inhibitors--where now for endocrine sequencing?Stephen R Johnston, Lesley-Ann Martin, Mitch Dowsett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2014
Interpreting plasma estrogen levels in breast cancer: caution neededElizabeth J Folkerd, Per E Lønning, Mitch Dowsett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2016
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast CancerMitch Dowsett, Per E Lønning, Nancy E Davidson
Molecular and Cellular Endocrinology|January 25, 2011
New and translational perspectives of oestrogen deprivation in breast cancerAnita K Dunbier, Lesley-Ann Martin, Mitch Dowsett
Breast (Edinburgh, Scotland)|October 4, 2005
The biology of steroid hormones and endocrine treatment of breast cancerMitch Dowsett, Elizabeth Folkerd, Deborah Doody, et al.
Breast Cancer Research and Treatment|November 22, 2020
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancerJuliet Richman, Alistair Ring, Mitch Dowsett, et al.
BMC Medicine|April 21, 2011
Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's boxCaterina Marchiò, Mitch Dowsett, Jorge S Reis-Filho
The Journal of Steroid Biochemistry and Molecular Biology|July 3, 2007
Predictors of response to aromatase inhibitorsHelen Anderson, Serdar Bulun, Ian Smith, et al.
Nature Clinical Practice. Oncology|August 31, 2007
Mechanisms of disease: angiogenesis and the management of breast cancerSusana Banerjee, Mitch Dowsett, Alan Ashworth, et al.
Pageof 36

Showing results (51-60 of 359) with videos related to

Sort By:
Pageof 36
European Journal of Cancer (Oxford, England : 1990)|February 11, 2014
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitorsPer Eystein Lønning, Benjamin P Haynes, Mitch Dowsett
Breast Cancer Research and Treatment|October 26, 2005
Life following aromatase inhibitors--where now for endocrine sequencing?Stephen R Johnston, Lesley-Ann Martin, Mitch Dowsett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2014
Interpreting plasma estrogen levels in breast cancer: caution neededElizabeth J Folkerd, Per E Lønning, Mitch Dowsett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2016
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast CancerMitch Dowsett, Per E Lønning, Nancy E Davidson
Molecular and Cellular Endocrinology|January 25, 2011
New and translational perspectives of oestrogen deprivation in breast cancerAnita K Dunbier, Lesley-Ann Martin, Mitch Dowsett
Breast (Edinburgh, Scotland)|October 4, 2005
The biology of steroid hormones and endocrine treatment of breast cancerMitch Dowsett, Elizabeth Folkerd, Deborah Doody, et al.
Breast Cancer Research and Treatment|November 22, 2020
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancerJuliet Richman, Alistair Ring, Mitch Dowsett, et al.
BMC Medicine|April 21, 2011
Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's boxCaterina Marchiò, Mitch Dowsett, Jorge S Reis-Filho
The Journal of Steroid Biochemistry and Molecular Biology|July 3, 2007
Predictors of response to aromatase inhibitorsHelen Anderson, Serdar Bulun, Ian Smith, et al.
Nature Clinical Practice. Oncology|August 31, 2007
Mechanisms of disease: angiogenesis and the management of breast cancerSusana Banerjee, Mitch Dowsett, Alan Ashworth, et al.
Pageof 36